NEW YORK, Jan. 30-Iconix Pharmaceuticals and the Schering-Plough Research Institute will collaborate in toxicogenomic marker research, Iconix said today.
The partners will look for new biomarkers related to toxic responses in the liver, kidney, and heart that may be used in early stage drug development.
Intellectual property details and financial specifics of this partnership were not available.
The Schering-Plough Research Institute is the pharmaceutical R&D division of Schering-Plough.
Iconix is a privately held company focusing on developing chemogenomics capabilities. It is based in Mountain View, Calif.